Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Qiaorui Tan"'
Autor:
Menghua HU, Qiaorui TAN, Weilin PU, Min DU, Wenzhen TU, Dayan SUN, Jingyi YANG, Yifei GU, Jiucun WANG, Xiangzhen KONG
Publikováno v:
Pifu-xingbing zhenliaoxue zazhi, Vol 31, Iss 5, Pp 303-312 (2024)
Objective To identify the effective components and key molecules of Yiqi Huoxu compound(YQHX) in the treatment of pulmonary inflammation and fibrosis in scleroderma, providing basis for the development of drug targets for scleroderma. Methods A mouse
Externí odkaz:
https://doaj.org/article/6b477a922d844156a3989e90ac05ea78
Autor:
Shujuan Sun, Xiaochu Man, Dongdong Zhou, Fangchao Zheng, Jiuda Zhao, Xuesong Chen, Tong Liu, Jie Huang, Qiaorui Tan, Na Li, Huihui Li
Publikováno v:
Cancer Medicine, Vol 12, Iss 18, Pp 18850-18860 (2023)
Abstract Purpose The prognostic outcomes of metastasis patterns in patients with de novo metastatic breast cancer (dnMBC) of different ages are unknown. Our study used a large‐scale data to investigate the metastasis patterns and prognostic feature
Externí odkaz:
https://doaj.org/article/ca4a699ff48842588a123bd7d463f894
Autor:
Sha Yin, Yajing Chi, Yangyang Du, Jingfen Wang, Changping Shan, Weiwei Yi, Mao Shang, Xiaochu Man, Qiaorui Tan, Huihui Li
Publikováno v:
Cancer Medicine, Vol 12, Iss 3, Pp 2333-2344 (2023)
Abstract Background Pyrotinib, a novel irreversible epidermal growth factor receptor 2 (EGFR)/HER2 dual tyrosine kinase inhibitor, has shown promising antitumor efficacy with tolerable toxicity in HER2‐positive metastatic breast cancer (MBC) in sev
Externí odkaz:
https://doaj.org/article/462a0e8cef044d55a9f601770ef2bba2
Autor:
Qiaorui Tan, Yajing Chi, Mu Su, Jinxing Zhou, Dongdong Zhou, Fangchao Zheng, Xiaochu Man, Shujuan Sun, Jie Huang, Huihui Li
Publikováno v:
Frontiers in Genetics, Vol 14 (2023)
Background: In recent years, tumor immunotherapy has become a viable treatment option for triple negative breast cancer (TNBC). Among these, immune checkpoint inhibitors (ICIs) have demonstrated good efficacy in advanced TNBC patients with programmed
Externí odkaz:
https://doaj.org/article/a4c2d839aa8049a1a7ba9a6b213e1e7a
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
As an aggressive subtype of breast cancer, triple-negative breast cancer (TNBC) is associated with poor prognosis and lack of effective therapy, except chemotherapy. In recent years, immunotherapy based on immune checkpoint (IC) inhibition has emerge
Externí odkaz:
https://doaj.org/article/09ad7adbd0c248909dc02502e5489a7e
Autor:
Mao Shang, Yajing Chi, Jianbo Zhang, Jin Chang, Hui Yang, Sha Yin, Qiaorui Tan, Xiaochu Man, Huihui Li
Publikováno v:
Frontiers in Oncology, Vol 11 (2022)
IntroductionNeoadjuvant trastuzumab plus chemotherapy may affect programmed death-ligand 1 (PD-L1) expression and tumor-infiltrating lymphocytes (TILs) in HER2-positive breast cancer. Discordant results were shown on the correlation between PD-L1 exp
Externí odkaz:
https://doaj.org/article/54712d6ac5ad4e7f88624298129bee55
Autor:
Huihui Li, Qiaorui Tan, Shujuan Sun, Dongdong Zhou, Bo Yu, Mu Su, Baojiang Li, Shu Fang, Ling Qiang, Guohua Ren, Bing Bu, Sha Yin, Xiaochu Man, Pengfei Qiu, Xinzhao Wang, Chao Li, Fangli Cao, Qian Shao, Dali Han, Lihua Song, Bingjie Fan, Baoxuan Zhang, Liang Xu, Xianguang Zhao, Yuqian Liao, Xuemei Xie, Lanping Liu
Publikováno v:
Cancer Research. 83:OT1-05
Background: Anti-PD-1 antibody combined with antiangiogenic drugs have demonstrated antitumor activity in advanced triple negative breast cancer (TNBC). Anlotinib, an oral multi-targeted tyrosine kinase inhibitor (TKI), has synergistic effect with an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c16f6da67d580004000db6bcd29648a
https://doi.org/10.1158/1538-7445.sabcs22-ot1-05-02
https://doi.org/10.1158/1538-7445.sabcs22-ot1-05-02
Autor:
Huihui Li, Jie Huang, Qiaorui Tan, Xiaochu Man, Sha Yin, Shujuan Sun, Yu Hu, Wenhuan Li, Dongdong Zhou, Lihua Song, Baoxuan Zhang, Liang Xu, Xinzhao Wang, Xuemei Xie
Publikováno v:
Cancer Research. 83:P1-14
Background: An estimated 30-50% of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) will develop brain metastases (BMs), and there are few effective treatment options. Pyrotinib has shown good effi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4857af4dfdda1f0d53f0eacbd96cc3cc
https://doi.org/10.1158/1538-7445.sabcs22-p1-14-03
https://doi.org/10.1158/1538-7445.sabcs22-p1-14-03
Publikováno v:
Cancer Research. 83:P3-05
Background: It is vital to find the risk genes and loci related to recurrence and metastasis in breast cancer (BC) patients. The Genome-wide association study (GWAS) can detect the risk of single nucleotide polymorphism (SNP) and help us understand t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::df7d8a146f48052ee76b1871f15878f9
https://doi.org/10.1158/1538-7445.sabcs22-p3-05-31
https://doi.org/10.1158/1538-7445.sabcs22-p3-05-31
Autor:
Huihui Li, Yajing Chi, Sha Yin, Bo Yu, Mu Su, Baoxuan Zhang, Ling Qiang, Guohua Ren, Lihua Song, Bing Bu, Shu Fang, Mao Shang, Qiaorui Tan, Xiaochu Man
Publikováno v:
Cancer Research. 82:P1-08
Background: Chemotherapy is the main treatment for metastatic triple-negative breast cancer (mTNBC). However, mTNBC patients (pts) is often associated with chemotherapy resistance and poor prognosis. Biomarkers that can effectively predict the effica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6fd6f867cf46eaffd4e047c6c8b35fef
https://doi.org/10.1158/1538-7445.sabcs21-p1-08-27
https://doi.org/10.1158/1538-7445.sabcs21-p1-08-27